A.P. Pharma Inc.

XenoPort to Release Third Quarter Financial Results on November 3, 2009.(Financial report)
Investment Weekly News; 11/14/2009; 786 words; ...at approximately 4:00 p.m. Eastern Time. The...conference call at 4:30 p.m. Eastern Time that...that same day after 8:00 p.m. Eastern Time, via...About XenoPort XenoPort, Inc. is a biopharmaceutical...collaboration with Astellas Pharma Inc. and GlaxoSmithKline...

A.P. Pharma to Transfer to Nasdaq Capital Market.
Biotech Week; 11/11/2009; 737 words; A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical...governance standards (see also A.P. Pharma, Inc.). As previously announced, the...Stock Market, Pharmaceuticals, A.P. Pharma Inc. This article was prepared by Biotech...

Dey Launches and Unveils Next-Generation, Needle-Protected EpiPen[R] (Epinephrine) Auto-Injector with Enhanced Patient-Friendly Features.
Biotech Week; 11/11/2009; 726 words; Dey Pharma, L.P., a subsidiary of Mylan Inc. (NASDAQ:MYL), today launched a newly designed, patient...Epinephrine, Pharmaceuticals, Therapy, Treatment, Dey Pharma L.P. This article was prepared by Biotech Week editors from staff...

Sepracor Announces Tender Offer for 0% Convertible Senior Subordinated Notes Due 2024.
Biotech Week; 11/11/2009; 892 words; Sepracor Inc. ("Sepracor") announced...offer will expire at 5:00 p.m., New York City time...Sepracor commenced by Aptiom, Inc., a Delaware corporation...subsidiary of Dainippon Sumitomo Pharma Co., Ltd., a joint...Pharmaceutical Company, Sepracor Inc.. This article was prepared...

Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer.
Cancer Weekly; 11/10/2009; 1225 words; Astellas Pharma Inc. ("Astellas") and Medivation...Astellas for MDV3100 and Pfizer, Inc for dimebon (latrepirdine...and Aquilo Partners, L.P. Astellas' legal adviser...LLP. Keywords: Astellas Pharma Inc., Astellas US LLC, Chemotherapy...